🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢Nuevo podcast📢 Todo lo que hay que saber de #oncogeriatria Gracias, Alicia Castelo por tu tiempo y conocimiento 🥰

Our latest review on #immunotherapy for #BiliaryMalignancies and #HCC published in #CancerTreatmentReviews 📸 1 - HCC 📸 2 - BTC

It has been an absolute pleasure to work with this 🤩 team on the latest EASLnews #guidelines on #extrahepatic #CCA 📝📚🔍

Happening in 📍Mallorca 🥳🥳 #AnaLanda presenting the WG3 Precision-BTC-Network #Consensus on #AmpullaryCancer by ENSCCA_2020 Work in progress 🏋️‍♀️ Recommendations ready📝 Delphi awaited 🤞🏻 Lets standardise the management of this cancer 💪 Asociación de Tumores de Vías Biliares AMMF Cholangiocarcinoma Foundation COST Academy

We continue with a whole session on the WG3 Precision-BTC-Network ENSCCA_2020 projects in #BiliaryMalignancies! Thank you to all speakers: -ampullary -targeted therapies -new markers - biliary stenting It is an absolute pleasure to co-lead this WG with Anna Saborowski 🙏 COST Academy

Insightfull messages from our #PatientAdvocacyGroups involved in the ENSCCA_2020 Precision-BTC-Network -AMMF -management in expert centres -Asociación de Tumores de Vías Biliares -support of clinicians to grow -#apic-never forget those who left us 🥂 to many new associations to come 💚💚💚 COST Academy

Thank you so much Precision-BTC-Network and Cholangiocarcinoma Foundation! Mentoring programs identify our future leaders and are worth every second we invest on them “A mentor empowers a person to see a possible future, and believe it can be achieved” (I had the best mentor ever #ProfJuanValle 😊)

#ESMOMembers vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee 📽️ Watch the ESMO President’s message 🔗 Vote now: ow.ly/XX3W50VZQyL FabriceAndre

#ASCO25 started with very interesting data on #NET Jaume Capdevila from Vall d’Hebron Institute of Oncology (VHIO) on #obrixtamig in #epNEC BITE-Phase I Manageable safety (CRS) Higher ORR and longer DOR if highDLL3 DAREON-5 trial ongoing in highDLL3 Combos with chemo for lowDLL3? Grupo GETNE ASCO NET- ESPAÑA

Developmental Therapeutics in #NEC 🥳🥳 with novel #immunotherapy at #ASCO25 Phase Ib/II LBL-024: PD-L1 /41BB + PlatinumEtoposide epNEC - first line Liver tox ✅ Myelosupression ⚠️ ORR 75% (durable) Great discussion by #GuillemArgiles 👏🏻 ASCO Kristof V Grupo GETNE

I am so glad to see a study focused on #fibrolamellar carcinoma at #ASCO25 #Vaccine against DNAJ-PKAc With IpiNivo Phase I study Encouraging results 🤞🏻 ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

Fantastic discussion by #BrianWolpin on #PDAC studies at #ASCO25 Further details on each one coming soon 😉 ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

#PDAC trial at #ASCO25 Resectable - borderline resectable stage #Casandra trial Neoadjuvant PAXG vs FOLFIRINOX Improved EFS Other primary end-points promising Not sure if I will be changing my current chemo choice But supports neoadjuvant (again) 😉 ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

#PDAC trial at #ASCO25 Metastatic setting - first line #Elraglusib + GemNabPaclitaxel Improved OS Phase III confirmatory data required ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

#POLCAGB trial in locally advanced #GallbladderCancer at #ASCO25 Neoadjuvant CisGem +/- ChemoRad 📊OS and ORR improved 🔪84-77% R0/1 👀Higher postoperative complications 🚨Small sample size Changes my practice? Maybe…. In an “adapted” format 🤔 ASCO SEOM Grupo Español de Tratamiento de Tumores Digestivos

ACO-GAIN trial at #ASCO25 ASCO Took me some time to get my thoughts on this 🧐 NeoAdj CisGem vs Surgery (SOC arm) for Loc+LocAdv BTC 😱25%mortality in SOC 🤯can “LocAdv” and “resectable” coexist? For LocAdv- SYSTEMIC FIRST PLEASE!! 🔜definitions by ENSCCA_2020 Precision-BTC-Network

MiniOral session at #ASCO25 in HPB-NET -ADC Claudine18.2: IBI343 in PDAC ORR 22%🤞🏻 -ADC CEACAM5/6: EBC129 in PDAC ORR 20% 🤞🏻 -10y follow-up Pembro (hMSI) - ORR consistent+high = Test, test, test🧬 -CABINET: cabo in p/epNET - global QoL improved 😊 ASCO Grupo Español de Tratamiento de Tumores Digestivos SEOM

📸 from yesterday at #ASCO25 Cholangiocarcinoma turned from #Green to #Pink for a few hours! 💚💗💚 #MatchingJackets at ASCO Teresa Macarulla 🥰 TIAN TIAN - great pic 😎